Aptar Pharma
About Aptar Pharma
Categories
-
FR
-
2015On CPHI since
-
5000+Employees
Company types
Primary activities
Meet us at
Pharmapack Europe 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
22 Jan 2025 - 23 Jan 2025
CPHI Frankfurt 2025
Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
Products from Aptar Pharma (1)
-
Product APF Futurity(R)
APF Futurity® is our first completely recyclable metal-free nasal spray pump, developed to deliver preservative-free multi-dose nasal saline and comparable OTC formulations.
APF Futurity® has been certified for complete recyclability by cyclosHTP (GER, NL, IRE) and achieves t...
Aptar Pharma Resources (3)
-
Video Innovations in Inhalation
Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems. -
Video The Pharma Challenge With Scope 3 Emissions – Collaborative Ways to Reduce Our CO2 Footprint
Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product -
Brochure Aptar Pharma Brochure
Aptar Pharma Brochure
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance